# A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

> **NCT04399837** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 123 (actual)

## Conditions studied

- Generalized Pustular Psoriasis

## Interventions

- **DRUG:** Spesolimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04399837
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-04
- **Primary completion:** 2022-11-23
- **Final completion:** 2022-11-23
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04399837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04399837, "A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04399837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*